Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mass
3 S&P 500 Stocks to Rival Nvidia's 2023 Performance in the Second Half of 2024
08:00am, Saturday, 11'th May 2024
The extraordinary performance of Nvidia (NASDAQ: NVDA ) in 2023 coincided with a seismic generative-AI rally that carried the entirety of the S&P 500 higher in a year that was punctuated by Fed intere
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
06:30am, Thursday, 09'th May 2024
Here's a question for you: What determines the value of a drug? Is it the number of lives it saves or how much it costs to make?
Biogen Reports Progress on Corporate Responsibility Priorities
07:30am, Thursday, 02'nd May 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company's commitment to
7 Retirement Stocks to Buy at a 52-Week Low in April
10:03am, Monday, 29'th Apr 2024
One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It's even better if you're buying into a reputable co
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
04:05pm, Thursday, 25'th Apr 2024
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ad
Why Biogen Stock Leaped Nearly 5% Higher Today
06:18pm, Wednesday, 24'th Apr 2024
The biotech handily beat the average analyst estimate for profitability. Investors were surely happy about this, but they might have been more impressed by the sales of a promising drug that recently
3-Stock Lunch: TXN, BIIB & CMG
05:05pm, Wednesday, 24'th Apr 2024
Jerry Castellini, Castle Ark co-founder, joins ‘Power Lunch' to discuss plays for three stocks including: Texas Instruments, Biogen and Chipotle Mexican.
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
02:01pm, Wednesday, 24'th Apr 2024
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript
11:25am, Wednesday, 24'th Apr 2024
Biogen Inc. (NASDAQ:BIIB ) Q1 2024 Earnings Call Transcript April 24, 2024 5:00 PM ET Company Participants Chuck Triano - Head of Investor Relations Chris Viehbacher - President and Chief Executive Of
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Wednesday, 24'th Apr 2024
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street e
Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales
08:51am, Wednesday, 24'th Apr 2024
Biogen says first-quarter global in-market sales of Leqembi were about $19 million, nearly triple the fourth quarter of 2023.
Biogen Q1 2024 results surpass expectation despite revenue decline
07:45am, Wednesday, 24'th Apr 2024
Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges. In the first quar
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
06:48am, Wednesday, 24'th Apr 2024
Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older drugs face fierce competition.
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
06:47am, Wednesday, 24'th Apr 2024
Alzheimer's drug Leqembi brought in in approximately $19 million in sales for the quarter, up from the $10 million the drug generated last year.
